Ionis Pharmaceuticals Presents at Barclays Healthcare Conference

CEO Brett Monia discusses the company's transformational year ahead with key catalysts for its genetic medicines pipeline.

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Ionis Pharmaceuticals, a leading genetic medicines company, presented at the Barclays 28th Annual Global Healthcare Conference in Miami. CEO Brett Monia provided an overview of the company's platform and portfolio, highlighting the momentum built in 2025 with the successful launch of its first two independent medicines, including Tryngolza for familial chylomicronemia syndrome (FCS). Monia noted that 2026 is set to be a transformational year for Ionis with a robust pipeline of catalysts on the horizon.

Why it matters

Ionis is at the forefront of genetic medicine development, leveraging its RNA-targeting platform to address diseases with high unmet needs. The company's ability to successfully launch its own medicines and maintain a strong pipeline of potential therapies is crucial for its continued growth and impact in the biotech industry.

The details

In 2025, Ionis launched its first two independent medicines, including Tryngolza for familial chylomicronemia syndrome (FCS), which generated $108 million in total revenue for the year and exceeded expectations. Monia stated that 2026 is poised to be a transformational year for the company, with a robust pipeline of catalysts on the horizon as it continues to develop novel genetic medicines.

  • Ionis launched its first two independent medicines in 2025.
  • Ionis presented at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026.

The players

Ionis Pharmaceuticals, Inc.

A genetic medicines company focused on developing novel treatments targeting RNA for clinical medicine, with a focus on diseases with high unmet needs.

Brett Monia

The Founder, CEO, and Director of Ionis Pharmaceuticals, who provided an overview of the company's platform, portfolio, and upcoming catalysts.

Got photos? Submit your photos here. ›

What they’re saying

“2026 is really set up to be a big year for the company, a transformational year for the company. We have so much coming. And that's really built on tremendous momentum that we established last year in 2025.”

— Brett Monia, Founder, CEO & Director (Seeking Alpha)

The takeaway

Ionis Pharmaceuticals is poised for continued growth and impact in the genetic medicine space, leveraging its RNA-targeting platform to address unmet medical needs. The successful launch of its first independent medicines in 2025 and the robust pipeline of catalysts for 2026 demonstrate the company's ability to translate its scientific expertise into tangible therapies for patients.